Silo Pharma (SILO) Research Hub

Silo Pharma (SILO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.16 USD (-1.69%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.62, market cap 0.00B. This hub links to the full technical, earnings and options research available for SILO.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close1.16 USD (-1.69%)
52-week range1.1 USD – 7.95 USD
Trend regimeRange
14-day RSI22.6 (Oversold)
Trailing P/E-0.62
Market cap0.00B
Dividend yield0.00%
Next earnings2026-09-02

Available research for SILO

Earnings

SILO earnings date and last-quarter result: next report 2026-09-02, last quarter beat, P/E -0.62. Updated 2026-07-23.

Options: Covered Call

Covered Call on SILO: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on SILO: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on SILO: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

SILO technical analysis: range, last 1.16 USD, RSI 22.6, 52w range 1.1 USD–7.95 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is SILO in?

Silo Pharma (SILO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is SILO in an uptrend or downtrend?

As of 2026-10-26, SILO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is SILO's trailing P/E ratio?

SILO's trailing P/E is -0.62, with a market cap of 0.00B. See the earnings research page for full valuation detail.

When does SILO next report earnings?

SILO is next scheduled to report earnings on 2026-09-02.